An Observational Study Comparing Delandistrogene Moxeparvovec (ELEVIDYS) With Standard of Care in Participants With Duchenne Muscular Dystrophy

NCT06270719 · clinicaltrials.gov ↗

ENROLLING_BY_INVITATION

Status

500

Enrollment

INDUSTRY

Sponsor class

Conditions

Duchenne Muscular Dystrophy

Interventions

GENETIC: Delandistrogene Moxeparvovec
DRUG: Standard of Care

Sponsor

Sarepta Therapeutics, Inc.